{
    "nct_id": "NCT05775159",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2023-03-20",
    "study_start_date": "2023-04-24",
    "study_completion_date": "",
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: Rilvegostomig"
            },
            {
                "drug_name": "Drug: Gemcitabine"
            },
            {
                "drug_name": "Drug: Cisplatin"
            },
            {
                "drug_name": "Drug: Lenvatinib"
            },
            {
                "drug_name": "Drug: Bevacizumab"
            },
            {
                "drug_name": "Drug: Volrustomig"
            }
        ]
    },
    "long_title": "A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)",
    "last_updated": "2025-07-03",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE2",
    "principal_investigator": "NA, Stephen Chan",
    "principal_investigator_institution": "AstraZeneca, CUHK",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [
        "HCC073"
    ],
    "protocol_no": "",
    "protocol_target_accrual": 260,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "* Age \u226518 years at the time of signing the ICF.",
        "* Provision of a signed and dated written ICF.",
        "* Confirmed locally advanced or metastatic solid tumor specified in substudy based on histopathology.",
        "* Adequate organ and bone marrow function.",
        "* At least 1 measurable not previously irradiated lesion per RECIST 1.1",
        "* Life expectancy of at least 12 weeks at the time of screening.",
        "* Willing and able to provide an adequate tumor sample.",
        "Exclude - Exclusion Criteria:",
        "Exclude - * History of allogeneic organ transplantation.",
        "Exclude - * Active or prior documented autoimmune or inflammatory disorders.",
        "Exclude - * Uncontrolled intercurrent illness.",
        "Exclude - * History of another primary malignancy, leptomeningeal carcinomatosis, and active primary immunodeficiency.",
        "Exclude - * Active infection, brain metastases or spinal cord compression.",
        "Exclude - * Participants co-infected with HBV and hepatitis D virus (HDV).",
        "Exclude - * Previous treatment in the present study.",
        "Exclude - * For substudy 1, history of hepatic encephalopathy within 12 months prior to treatment allocation."
    ],
    "short_title": "Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "AstraZeneca",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "Cohort 1A",
                        "arm_internal_id": 0,
                        "arm_description": "Volrustomig monotherapy",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Volrustomig",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Cohort 1B",
                        "arm_internal_id": 1,
                        "arm_description": "Volrustomig combination with bevacizumab",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Volrustomig",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Bevacizumab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Cohort 1C",
                        "arm_internal_id": 2,
                        "arm_description": "Volrustomig combination with lenvatinib",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Volrustomig",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Lenvatinib",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Cohort 2A",
                        "arm_internal_id": 3,
                        "arm_description": "Rilvegostomig combination with Gemcitabine and Cisplatin",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Rilvegostomig",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Gemcitabine",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Cisplatin",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Cohort 2B",
                        "arm_internal_id": 4,
                        "arm_description": "Volrustomig combination with Gemcitabine and Cisplatin",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Volrustomig",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Gemcitabine",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Cisplatin",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Cohort 1D",
                        "arm_internal_id": 5,
                        "arm_description": "Volrustomig combination with rilvegostomig and bevacizumab",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Volrustomig",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Bevacizumab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Rilvegostomig",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Cohort 1E",
                        "arm_internal_id": 6,
                        "arm_description": "Rilvegostomig combination with bevacizumab",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Bevacizumab",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Rilvegostomig",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "or": [
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Intraductal Papillary Neoplasm of the Bile Duct"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Hepatocellular Carcinoma"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Intracholecystic Papillary Neoplasm"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Fibrolamellar Carcinoma"
                                        }
                                    }
                                ]
                            },
                            {
                                "clinical": {
                                    "age_numerical": ">=18",
                                    "disease_status": [
                                        "Locally Advanced",
                                        "Metastatic"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        ]
    }
}